Related Experiment Video
Updated: Mar 21, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice
Wilma Helena Oliveira1, Ana Karolina Nunes2, Maria Eduarda Rocha França1
1Laboratório de Ultraestrutura, Centro de Pesquisas Aggeu Magalhães (CPqAM), PE, Brazil; Programa de Pós-graduação em Ciências Biológicas, Centro de Biociências, Universidade Federal de Pernambuco - UFPE, PE, Brazil.
Abstract:
The aim of the present study was to analyze the action of metformin on short-term memory, glial cell activation and neuroinflammation caused by experimental diabetic encephalopathy in C57BL/6 mice. Diabetes was induced by the intraperitoneal injection of a dose of 90mg/kg of streptozotocin on two successive days. Mice with blood glucose levels ≥200dl/ml were considered diabetic and were given metformin hydrochloride at doses of 100mg/kg and 200mg/kg (by gavage, twice daily) for 21 days. On the final day of treatment, the mice underwent a T-maze test. On the 22nd day of treatment all the animals were anesthetized and euthanized. Diabetic animals treated with metformin had a higher spatial memory score. The hippocampus of the diabetic animals presented reactive gliosis, neuronal loss, NF-kB signaling activation, and high levels of IL-1 and VEGF. In addition, the T-maze test scores of these animals were low. Treatment with metformin reduced the expression of GFAP, Iba-1 (astrocyte and microglial markers) and the inflammation markers (p-IKB, IL-1 and VEGF), while enhancing p-AMPK and eNOS levels and increasing neuronal survival (Fox-1 and NeuN). Treatment with metformin also improved the spatial memory scores of diabetic animals. In conclusion, the present study showed that metformin can significantly reduce neuroinflammation and can decrease the loss of neurons in the hippocampus of diabetic animals, which can subsequently promote improvements in spatial memory.
Insights
Metformin treatment improved spatial memory in diabetic mice by reducing neuroinflammation and neuronal loss in the hippocampus. This study highlights metformin's potential for treating diabetic encephalopathy.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- Diabetic encephalopathy is characterized by cognitive deficits, neuroinflammation, and neuronal loss.
- Streptozotocin-induced diabetes in mice serves as a model for studying diabetic complications.
- Metformin is a widely used antidiabetic drug with potential neuroprotective effects.
Purpose of the Study:
- To investigate the effects of metformin on short-term memory, glial cell activation, and neuroinflammation in experimental diabetic encephalopathy.
- To analyze metformin's impact on hippocampal neuronal survival and related signaling pathways.
Main Methods:
- Diabetes was induced in C57BL/6 mice using streptozotocin.
- Diabetic mice were treated with metformin (100mg/kg and 200mg/kg) for 21 days.
- Spatial memory was assessed using the T-maze test; neuroinflammation and neuronal survival markers were analyzed post-mortem.
Main Results:
- Metformin treatment significantly improved spatial memory scores in diabetic mice.
- Metformin reduced glial cell activation (GFAP, Iba-1), neuroinflammation (NF-kB, IL-1, VEGF), and neuronal loss (Fox-1, NeuN) in the hippocampus.
- Enhanced levels of p-AMPK and eNOS were observed in metformin-treated diabetic mice.
Conclusions:
- Metformin effectively mitigates neuroinflammation and neuronal loss in the hippocampus of diabetic mice.
- Metformin treatment demonstrates potential therapeutic benefits for cognitive impairments associated with diabetic encephalopathy.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Psychoneuroimmunology: Diabetes and Cancer

